SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-40212
Connect Biopharma Holdings Limited
(Translation of registrants name into English)
12265 El Camino Real, Suite 350
San Diego, CA 92130
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 17, 2022, Connect Biopharma Holdings Limited (the Company) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.
The Company was previously notified by Nasdaq on June 16, 2022, that it was not in compliance with the minimum bid price requirement because the Companys American Depositary Shares (ADSs) had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. To regain compliance, the Companys ADSs were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on August 16, 2022.
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration No. 333-264340) and Form S-8 (Registration Nos. 333-254524 and 333-266006) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Dated: August 19, 2022
|CONNECT BIOPHARMA HOLDINGS LIMITED
|Name: Steven Chan
|Title: Chief Financial Officer